Placentia, California — May 5, 2026 — Leads & Copy — InVitro International (OTCQB: IVRO) reported its FY ’26 Q2 sales reached $206,840, a 5.3% increase compared to the same period in FY ’25.
Year-to-date sales of $389,440 are 11.6% below the first half of FY ’25. The company’s FY ’26 Q2 net income of $17,556 was 14.7% higher than Q2 of the previous year. However, the first half of FY ’26 net income is 42.8% lower than the first half of the last fiscal year.
CEO & Chairman W. Richard Ulmer noted that the second quarter financials were more promising than the first quarter, showing gains in both sales and net income compared to the previous year.
InVitro aims to achieve its 21st consecutive year of profitability while also advancing its new strategic direction. The company continues to identify global prospects as regulatory policies increasingly accept in vitro test results.
InVitro International, Inc., established in 1985 and based in Placentia, California, specializes in non-animal testing methods. Its testing technologies are designed to produce data, approved by Regulatory Agencies, regarding corrosivity and ocular/dermal irritation, correlating with animal and human test results. IVRO’s technology is commercialized worldwide through test kits and partner laboratory services.
Source: InVitro International
